公开(公告)号：US20190211022A1

公开(公告)日：2019-07-11

申请号：US16311638

申请日：2017-06-19

Applicant: NOVARTIS AG

Inventor： Ying HUANG ,  Bo LIU ,  Liang MAO ,  Long WANG ,  Liladhar Murlidhar WAYKOLE ,  Lijun ZHANG

IPC: C07D487/04 ,  A61K31/519 ,  A61P35/00 ,  A61P35/02

CPC classification number: C07D487/04 ,  A61K31/519 ,  A61P35/00 ,  A61P35/02 ,  C07B2200/13

Abstract: Provided herein are crystalline forms of a triazolopyrimidine compound, which is useful for treating a PRC2-mediated disease or disorder.

公开(公告)号：US20140011798A1

公开(公告)日：2014-01-09

申请号：US13748790

申请日：2013-01-24

Applicant: NOVARTIS AG

Inventor： Pascal FURET ,  Vito GUAGNANO ,  Philipp HOLZER ,  Joerg KALLEN ,  Lv LIAO ,  Robert MAH ,  Liang MAO ,  Keiichi MASUYA ,  Achim SCHLAPBACH ,  Stefan STUTZ ,  Andrea VAUPEL

IPC: C07D487/04 ,  A61K31/4439 ,  A61K45/06 ,  A61K31/5377 ,  A61K31/501 ,  A61K31/541 ,  A61K31/4188 ,  A61K31/506

CPC classification number: C07D487/04 ,  A61K31/4188 ,  A61K31/4439 ,  A61K31/501 ,  A61K31/506 ,  A61K31/5377 ,  A61K31/541 ,  A61K45/06

Abstract: The invention relates to compounds of formula (I): as described herein, pharmaceutical preparations comprising such compounds, uses and methods of use for such compounds in the treatment of a disorder or a disease mediated by the activity of MDM2 and/or MDM4, and combinations comprising such compounds.

公开(公告)号：US20140343084A1

公开(公告)日：2014-11-20

申请号：US14327639

申请日：2014-07-10

Applicant: Novartis AG

Inventor： Pascal FURET ,  Vito GUAGNANO ,  Philipp HOLZER ,  Joerg KALLEN ,  Lv LIAO ,  Robert MAH ,  Liang MAO ,  Keiichi MASUYA ,  Achim SCHLAPBACH ,  Stefan STUTZ ,  Andrea VAUPEL

IPC: C07D487/04

CPC classification number: C07D487/04 ,  A61K31/4188 ,  A61K31/4439 ,  A61K31/501 ,  A61K31/506 ,  A61K31/5377 ,  A61K31/541 ,  A61K45/06

Abstract: The invention relates to compounds of formula (I): as described herein, pharmaceutical preparations comprising such compounds, uses and methods of use for such compounds in the treatment of a disorder or a disease mediated by the activity of MDM2 and/or MDM4, and combinations comprising such compounds.

Abstract translation: 本发明涉及式（I）化合物：如本文所述，包含这些化合物的药物制剂，用于治疗由MDM2和/或MDM4的活性介导的疾病或疾病的这些化合物的用途和方法，以及 包含这些化合物的组合。